~~<i id='550EDBBBAE'><strike id='550EDBBBAE'><tt id='550EDBBBAE'><pre id='550EDBBBAE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：fashion 2025-10-01 21:48:39 - browse：14

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： New weight loss drugs vying to be the next Wegovy or Mounjaro

Wikipedia

entertainment

explore

hotspot

knowledge

AdobeWhatwillhappenifAmericanslosetheconstitutionalrighttoabortion?Notallwomenwhoneedanabortionwould

WSS

FDA panel endorses Alnylam’s heart drug — after picking it apart

Phenylephrine and the overlooked value of the placebo effect

Senate panel eyes new effort on drug shortages

A common UTI test for kids haunts adults as a traumatic 'nightmare'

FDA proposes changes to key medical devices approval pathway

Phenylephrine and the overlooked value of the placebo effect

hotspot

focus

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Pig kidney works a record two months in donated body

Medical leaders decry Supreme Court decision on affirmative action

Bristol 'take

The high cost of giving birth even with insurance

Liquid biopsy for lung cancer is launched by Delfi

Peter Hotez and the public health issue of online harassment

Private equity could exacerbate cardiology's overuse problem, experts fear

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A Q&A with the global head of Boehringer Ingelheim's innovation unit

entertainment

Why Charlie Gard's case is so disturbing to Americans

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Food makers to regulators: Ultra

VC firm General Catalyst wants to buy a health system

How medical schools plan to diversify without affirmative action

explore

explore

hotspot

knowledge